Oncol Nurs Forum:癌症影响癌症患者家属的健康行为

2015-02-24 Jessie 译 MedSci原创

Normal 0 10 pt 0 2 false false false EN-US ZH-CN X-NONE

患癌症被认为是对患者进行健康教育、促进健康行为和保持健康生活方式的好时机。许多癌症患者在知道诊断后都想生活的更健康,健康的生活方式有助于缓和癌症治疗的副作用,防止发生其他的慢性疾病,并减轻现存慢性疾病对生活质量的影响。但关于癌症经历对患者家庭成员健康行为影响的研究较少,而家庭成员的健康行为有助于提高患者的健康水平。癌症治疗结束时被认为是进行健康行为干预的最佳时机。近来,美国的一项研究调查了癌症对患者家属健康行为的影响及影响家属采取健康行为的因素。 该研究在美国中西部一所综合性癌症中心招募了39名癌症患者的家属及50名癌症患者,癌症种类包括乳腺癌、直肠癌、头颈部肿瘤、肺癌及前列腺癌。调查时间是患者完成治疗前3周内。家属们完成了问卷调查、面对面或电话结构访谈。调查的内容包括健康饮食、躯体活动及戒烟的意愿、感知益处和信心,情绪困扰,家庭凝聚力、冲突和表达性(expressiveness)。 研究发现,癌症患者的家庭成员具有较高水平的健康饮食、每天进行30分钟的中度躯体活动的意愿、感知益处及信心(3.54~6.69,可能的范围为1~7)。癌症经历增加了患者家属对患癌危险性的

版权声明:
本网站所有内容来源注明为“williamhill asia 医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于williamhill asia 医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“williamhill asia 医学”。其它来源的文章系转载文章,或“williamhill asia 号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与williamhill asia 联系,williamhill asia 将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1948027, encodeId=67ef194802e83, content=<a href='/topic/show?id=3eb75302455' target=_blank style='color:#2F92EE;'>#患者家属#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53024, encryptionId=3eb75302455, topicName=患者家属)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLIQxicGuURvblbKDmmdLreAdrFKYA57y7viabog6mfk8dXQpQzYCf0ibcgoMnFrQ2MiaV8Iic4ocdhEfw/132, createdBy=0e3a2500177, createdName=ms1692810954239974, createdTime=Mon Nov 02 17:42:00 CST 2015, time=2015-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864609, encodeId=5d0f1864609f9, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Wed Jun 03 08:42:00 CST 2015, time=2015-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=26246, encodeId=16012624687, content=mark, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=761999770, createdName=wingjoy2009, createdTime=Mon Jun 08 07:26:00 CST 2015, time=2015-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=23700, encodeId=0ac123e0094, content=很不错学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ac181616815, createdName=ljjj1053, createdTime=Sat May 16 19:30:00 CST 2015, time=2015-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=17163, encodeId=32461e1634a, content=好文章,超赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=36a81612921, createdName=xiaoai5777, createdTime=Fri Feb 27 23:11:00 CST 2015, time=2015-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289456, encodeId=128912894568e, content=<a href='/topic/show?id=cbb8e1356f7' target=_blank style='color:#2F92EE;'>#癌症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71356, encryptionId=cbb8e1356f7, topicName=癌症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ba218, createdName=zgwhgch, createdTime=Thu Feb 26 07:42:00 CST 2015, time=2015-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=17011, encodeId=19ba1e01174, content=不错的文章,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f2fb1607679, createdName=orthoW, createdTime=Wed Feb 25 17:52:00 CST 2015, time=2015-02-25, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1948027, encodeId=67ef194802e83, content=<a href='/topic/show?id=3eb75302455' target=_blank style='color:#2F92EE;'>#患者家属#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53024, encryptionId=3eb75302455, topicName=患者家属)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLIQxicGuURvblbKDmmdLreAdrFKYA57y7viabog6mfk8dXQpQzYCf0ibcgoMnFrQ2MiaV8Iic4ocdhEfw/132, createdBy=0e3a2500177, createdName=ms1692810954239974, createdTime=Mon Nov 02 17:42:00 CST 2015, time=2015-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864609, encodeId=5d0f1864609f9, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Wed Jun 03 08:42:00 CST 2015, time=2015-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=26246, encodeId=16012624687, content=mark, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=761999770, createdName=wingjoy2009, createdTime=Mon Jun 08 07:26:00 CST 2015, time=2015-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=23700, encodeId=0ac123e0094, content=很不错学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ac181616815, createdName=ljjj1053, createdTime=Sat May 16 19:30:00 CST 2015, time=2015-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=17163, encodeId=32461e1634a, content=好文章,超赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=36a81612921, createdName=xiaoai5777, createdTime=Fri Feb 27 23:11:00 CST 2015, time=2015-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289456, encodeId=128912894568e, content=<a href='/topic/show?id=cbb8e1356f7' target=_blank style='color:#2F92EE;'>#癌症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71356, encryptionId=cbb8e1356f7, topicName=癌症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ba218, createdName=zgwhgch, createdTime=Thu Feb 26 07:42:00 CST 2015, time=2015-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=17011, encodeId=19ba1e01174, content=不错的文章,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f2fb1607679, createdName=orthoW, createdTime=Wed Feb 25 17:52:00 CST 2015, time=2015-02-25, status=1, ipAttribution=)]
    2015-06-03 minlingfeng
  3. [GetPortalCommentsPageByObjectIdResponse(id=1948027, encodeId=67ef194802e83, content=<a href='/topic/show?id=3eb75302455' target=_blank style='color:#2F92EE;'>#患者家属#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53024, encryptionId=3eb75302455, topicName=患者家属)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLIQxicGuURvblbKDmmdLreAdrFKYA57y7viabog6mfk8dXQpQzYCf0ibcgoMnFrQ2MiaV8Iic4ocdhEfw/132, createdBy=0e3a2500177, createdName=ms1692810954239974, createdTime=Mon Nov 02 17:42:00 CST 2015, time=2015-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864609, encodeId=5d0f1864609f9, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Wed Jun 03 08:42:00 CST 2015, time=2015-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=26246, encodeId=16012624687, content=mark, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=761999770, createdName=wingjoy2009, createdTime=Mon Jun 08 07:26:00 CST 2015, time=2015-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=23700, encodeId=0ac123e0094, content=很不错学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ac181616815, createdName=ljjj1053, createdTime=Sat May 16 19:30:00 CST 2015, time=2015-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=17163, encodeId=32461e1634a, content=好文章,超赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=36a81612921, createdName=xiaoai5777, createdTime=Fri Feb 27 23:11:00 CST 2015, time=2015-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289456, encodeId=128912894568e, content=<a href='/topic/show?id=cbb8e1356f7' target=_blank style='color:#2F92EE;'>#癌症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71356, encryptionId=cbb8e1356f7, topicName=癌症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ba218, createdName=zgwhgch, createdTime=Thu Feb 26 07:42:00 CST 2015, time=2015-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=17011, encodeId=19ba1e01174, content=不错的文章,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f2fb1607679, createdName=orthoW, createdTime=Wed Feb 25 17:52:00 CST 2015, time=2015-02-25, status=1, ipAttribution=)]
    2015-06-08 wingjoy2009

    mark

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1948027, encodeId=67ef194802e83, content=<a href='/topic/show?id=3eb75302455' target=_blank style='color:#2F92EE;'>#患者家属#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53024, encryptionId=3eb75302455, topicName=患者家属)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLIQxicGuURvblbKDmmdLreAdrFKYA57y7viabog6mfk8dXQpQzYCf0ibcgoMnFrQ2MiaV8Iic4ocdhEfw/132, createdBy=0e3a2500177, createdName=ms1692810954239974, createdTime=Mon Nov 02 17:42:00 CST 2015, time=2015-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864609, encodeId=5d0f1864609f9, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Wed Jun 03 08:42:00 CST 2015, time=2015-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=26246, encodeId=16012624687, content=mark, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=761999770, createdName=wingjoy2009, createdTime=Mon Jun 08 07:26:00 CST 2015, time=2015-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=23700, encodeId=0ac123e0094, content=很不错学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ac181616815, createdName=ljjj1053, createdTime=Sat May 16 19:30:00 CST 2015, time=2015-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=17163, encodeId=32461e1634a, content=好文章,超赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=36a81612921, createdName=xiaoai5777, createdTime=Fri Feb 27 23:11:00 CST 2015, time=2015-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289456, encodeId=128912894568e, content=<a href='/topic/show?id=cbb8e1356f7' target=_blank style='color:#2F92EE;'>#癌症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71356, encryptionId=cbb8e1356f7, topicName=癌症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ba218, createdName=zgwhgch, createdTime=Thu Feb 26 07:42:00 CST 2015, time=2015-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=17011, encodeId=19ba1e01174, content=不错的文章,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f2fb1607679, createdName=orthoW, createdTime=Wed Feb 25 17:52:00 CST 2015, time=2015-02-25, status=1, ipAttribution=)]
    2015-05-16 ljjj1053

    很不错学习了

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1948027, encodeId=67ef194802e83, content=<a href='/topic/show?id=3eb75302455' target=_blank style='color:#2F92EE;'>#患者家属#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53024, encryptionId=3eb75302455, topicName=患者家属)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLIQxicGuURvblbKDmmdLreAdrFKYA57y7viabog6mfk8dXQpQzYCf0ibcgoMnFrQ2MiaV8Iic4ocdhEfw/132, createdBy=0e3a2500177, createdName=ms1692810954239974, createdTime=Mon Nov 02 17:42:00 CST 2015, time=2015-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864609, encodeId=5d0f1864609f9, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Wed Jun 03 08:42:00 CST 2015, time=2015-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=26246, encodeId=16012624687, content=mark, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=761999770, createdName=wingjoy2009, createdTime=Mon Jun 08 07:26:00 CST 2015, time=2015-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=23700, encodeId=0ac123e0094, content=很不错学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ac181616815, createdName=ljjj1053, createdTime=Sat May 16 19:30:00 CST 2015, time=2015-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=17163, encodeId=32461e1634a, content=好文章,超赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=36a81612921, createdName=xiaoai5777, createdTime=Fri Feb 27 23:11:00 CST 2015, time=2015-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289456, encodeId=128912894568e, content=<a href='/topic/show?id=cbb8e1356f7' target=_blank style='color:#2F92EE;'>#癌症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71356, encryptionId=cbb8e1356f7, topicName=癌症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ba218, createdName=zgwhgch, createdTime=Thu Feb 26 07:42:00 CST 2015, time=2015-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=17011, encodeId=19ba1e01174, content=不错的文章,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f2fb1607679, createdName=orthoW, createdTime=Wed Feb 25 17:52:00 CST 2015, time=2015-02-25, status=1, ipAttribution=)]
    2015-02-27 xiaoai5777

    好文章,超赞

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1948027, encodeId=67ef194802e83, content=<a href='/topic/show?id=3eb75302455' target=_blank style='color:#2F92EE;'>#患者家属#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53024, encryptionId=3eb75302455, topicName=患者家属)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLIQxicGuURvblbKDmmdLreAdrFKYA57y7viabog6mfk8dXQpQzYCf0ibcgoMnFrQ2MiaV8Iic4ocdhEfw/132, createdBy=0e3a2500177, createdName=ms1692810954239974, createdTime=Mon Nov 02 17:42:00 CST 2015, time=2015-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864609, encodeId=5d0f1864609f9, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Wed Jun 03 08:42:00 CST 2015, time=2015-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=26246, encodeId=16012624687, content=mark, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=761999770, createdName=wingjoy2009, createdTime=Mon Jun 08 07:26:00 CST 2015, time=2015-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=23700, encodeId=0ac123e0094, content=很不错学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ac181616815, createdName=ljjj1053, createdTime=Sat May 16 19:30:00 CST 2015, time=2015-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=17163, encodeId=32461e1634a, content=好文章,超赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=36a81612921, createdName=xiaoai5777, createdTime=Fri Feb 27 23:11:00 CST 2015, time=2015-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289456, encodeId=128912894568e, content=<a href='/topic/show?id=cbb8e1356f7' target=_blank style='color:#2F92EE;'>#癌症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71356, encryptionId=cbb8e1356f7, topicName=癌症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ba218, createdName=zgwhgch, createdTime=Thu Feb 26 07:42:00 CST 2015, time=2015-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=17011, encodeId=19ba1e01174, content=不错的文章,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f2fb1607679, createdName=orthoW, createdTime=Wed Feb 25 17:52:00 CST 2015, time=2015-02-25, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1948027, encodeId=67ef194802e83, content=<a href='/topic/show?id=3eb75302455' target=_blank style='color:#2F92EE;'>#患者家属#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53024, encryptionId=3eb75302455, topicName=患者家属)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLIQxicGuURvblbKDmmdLreAdrFKYA57y7viabog6mfk8dXQpQzYCf0ibcgoMnFrQ2MiaV8Iic4ocdhEfw/132, createdBy=0e3a2500177, createdName=ms1692810954239974, createdTime=Mon Nov 02 17:42:00 CST 2015, time=2015-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864609, encodeId=5d0f1864609f9, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Wed Jun 03 08:42:00 CST 2015, time=2015-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=26246, encodeId=16012624687, content=mark, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=761999770, createdName=wingjoy2009, createdTime=Mon Jun 08 07:26:00 CST 2015, time=2015-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=23700, encodeId=0ac123e0094, content=很不错学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ac181616815, createdName=ljjj1053, createdTime=Sat May 16 19:30:00 CST 2015, time=2015-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=17163, encodeId=32461e1634a, content=好文章,超赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=36a81612921, createdName=xiaoai5777, createdTime=Fri Feb 27 23:11:00 CST 2015, time=2015-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289456, encodeId=128912894568e, content=<a href='/topic/show?id=cbb8e1356f7' target=_blank style='color:#2F92EE;'>#癌症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71356, encryptionId=cbb8e1356f7, topicName=癌症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ba218, createdName=zgwhgch, createdTime=Thu Feb 26 07:42:00 CST 2015, time=2015-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=17011, encodeId=19ba1e01174, content=不错的文章,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f2fb1607679, createdName=orthoW, createdTime=Wed Feb 25 17:52:00 CST 2015, time=2015-02-25, status=1, ipAttribution=)]
    2015-02-25 orthoW

    不错的文章,学习了

    0

相关威廉亚洲官网

JAMA Oncol:病人对癌症检测治疗的要求

JAMA Oncology近日刊文,报道了一项有关病人对癌症检测治疗的要求的研究。被采访的医生认为高昂的医疗费用主要是因为病人的需求,而非医生本身。然而,鲜有数据有关有需求的病人、病人需求的合理性已经医生对病人需求的依从性。研究人员对内科医生、研究院、执业护士和医生助理进行采访,询问他们病人是否做出对癌症检测治疗的需求以及类型和合理性。采访是在美国费城地区的三个肿瘤门诊进行的。 研究得出4个

STM:一种新的治疗癌症方法:电场送药

研究小组已经设计了一种新的靶向肿瘤的抗癌治疗方法,这一发现可能会对癌症患者的临床治疗有新的效果。 根据本周发表在《科学转化医学》杂志上的一项研究,所谓的例子电渗疗法,该技术可以选择特定区域进行高浓度化疗,从而减少损伤健康组织的风险。 生物医学工程与力学系和机械工程系助理教授说:“有许多药物面临的一大挑战是让他们去需要它们的地方。该技术主要是迫使药物直接通过肿瘤,使所有肿瘤细胞暴露在治疗区域内。

求证:性格与癌症也有关系吗

摘要:很多人认为,只要吃好、睡好、生活规律,癌症就会远离williamhill asia 。而一些肿瘤专家经过长期临床观察,得出一个结论,除了遗传和生活方式外,性格与癌症也有密切关系,并称之为“癌症性格”。 癌症与性格真能扯上关系? 正文“癌症性格”近日,首都医科大学肺癌诊疗中心主任、首都医科大学宣武医院胸外科主任、中国癌症基金会控烟与肺癌防治部主任支修益在接受《中国科学报》记者采访时表示,“癌症性格”这一提法很早就

CA:图说全新全球癌症统计数据

2015年2月4日,《CA:临床医师癌症杂志》(CA Cancer J Clin)在线公布了全球癌症统计数据。这是基于2012年癌症新发、死亡病例数统计(GLOBOCAN)得出,也是继2011年所公布的2008年统计数据后,时隔4年再次公布的最新结果,其意义可谓重大。williamhill asia 对2008年和2012年统计数据进行了分析和对比(如下图),目的是使癌症发病、死亡的趋势一目了然。对比结果显示,全球范围

JAMA Oncol:子宫肌瘤切除术后潜在的癌症

子宫肌瘤是子宫中的良性平滑肌瘤。这些肌瘤是很常见的,据估计20%-50%女性有子宫肌瘤。尽管子宫肌瘤通过是无症状的,但能造成疼痛、月经不调以及生育能力降低。子宫肌瘤切除术现在常常通过微创手术得以实现。电动分碎术,或者使用机械装置切除子宫肌瘤有可能被用于促进子宫肌瘤的切除。为了分析潜在的癌症和癌症前期变化的患病率,研究人员使用了美国国家数据库进行回顾性分析。数据是在2006年1月至2